CSIMarket Company Name, Ticker, Suppliers, else..
 
Ocugen Inc   (NASDAQ: OCGN)
 
Price: $1.0250 $-0.04 -3.756%
Day's High: $1.0950000286102295 Week Perf: -24.07 %
Day's Low: $ 1.01 30 Day Perf: -25.18 %
Volume (M): 22,053,305 52 Wk High: $ 2.72
Volume (M$): $ 0 52 Wk Avg: $1.50
Open: $1.10 52 Wk Low: $1.01



 Market Capitalization (Millions $) 347
 Shares Outstanding (Millions) 339
 Employees 116
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -82
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0

Business Description


Ocugen Inc. is a biopharmaceutical company based in the United States that specializes in developing gene therapies to treat rare inherited eye diseases. The company's main focus is on developing a potential cure for blindness-causing diseases, such as Retinitis Pigmentosa and Leber Congenital Amaurosis. Ocugen Inc. utilizes its own proprietary technology platform, known as OcuGene, to create gene therapies that aim to correct or replace defective genes in the eye. The company is actively involved in conducting clinical trials to evaluate the safety and efficacy of its gene therapies. Ocugen Inc. also collaborates with various research institutions and partners to advance its pipeline of therapeutic candidates.


   Company Address: 11 Great Valley Parkway Malvern 19355 PA
   Company Phone Number: 328-4701   Stock Exchange / Ticker: NASDAQ OCGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
FDMT   -9.71%    
FENC   -8.2%    
MRNA   -9.41%    
NVAX   -9.88%    
OTLK        5.62% 
RGNX   -10.83%    
• View Complete Report
   



Product Service News

Ocugen Advances OCU410ST for Stargardt Disease First Patient Dosed in Pivotal Clinical Trial

Published Fri, Jul 18 2025 12:11 PM UTC

In a significant development for the treatment of genetic eye diseases, Ocugen, Inc. announced that the first patient has been dosed in its Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST, a novel modifier gene therapy aimed at combating Stargardt disease, a form of inherited retinal degeneration associated with mutations in the ABCA4 gene. This milestone...
Clinical Study

Ocugens Odyssey Light Through Gene Therapy for Stargardt Disease,

Published Tue, May 27 2025 12:30 PM UTC

Charting Uncharted Waters: Ocugen s Ground-breaking Endeavours in Stargardt Disease Treatment In a realm where hope often flickers amidst shadow, Ocugen Inc. a luminary in the field of biotechnology, emerges as a beacon of promise for those navigating the murky waters of rare ocular diseases. Today, the cries for advancement in the battle against blindness are a little loud...
Clinical Study

DSMB Approves Continued Phase 2 Evaluation of Ocugens OCU410 Therapy for Geographic Atrophy,

Published Thu, Dec 19 2024 11:39 AM UTC

Data and Safety Monitoring Board Endorses Continued Investigation of OCU410 in Phase 2 ArMaDa Clinical Trial MALVERN, Pa. Dec. 19, 2024 Ocugen, Inc. (NASDAQ: OCGN), a pioneering biotechnology firm known for its focus on novel gene and cell therapies, biologics, and vaccines, has announced a significant development in its ongoing clinical research. The Data and Safety Monitor...
Clinical Study

Promising Horizons Insights into Ocugens OCU410 Gene Therapy for Geographic Atrophy Related to Dry Age-Related Macul...

Published Tue, Nov 19 2024 12:03 PM UTC

The recent announcement from Ocugen, Inc. regarding their preliminary findings from the OCU410 ArMaDa clinical trial sheds light on a potential breakthrough in treating geographic atrophy (GA), secondary to dry age-related macular degeneration (dAMD). As the prevalence of dAMD continues to rise globally, innovative therapies like OCU410 are pivotal in paving the way for bett...
Product Service News

“Ocugen Pioneering Paths in Gene Therapy for Rare Retinal Diseases,

Published Wed, Nov 20 2024 12:30 PM UTC

In an era where breakthroughs in biotechnology can redefine treatment landscapes for debilitating conditions, Ocugen, Inc. (NASDAQ: OCGN) is making significant strides with its gene therapy candidates targeting rare retinal diseases. This article will delineate Ocugen s recent accomplishments, particularly the European Medicines Agency (EMA) s granting of orphan medicinal pr...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 75.80
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.75
Working Capital Ratio 0.81
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.26 $
Revenues (TTM) 0.01 $
Cash Flow (TTM) 0.01 $
Cash 0.3 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 39,483
Net Income per Employee (TTM) -705,267
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.06

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -1105.11 %
Net Margin (MRQ) -1671.84 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Ocugen Inc's Segments
Reportable    203.09 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.